TRIESENCE (Triamcinolone Acetonide) Patent Expiration, LOE Window & CMS Spending
TRIESENCE (Triamcinolone Acetonide) by Harrow Eye: FDA Orange Book core substance LOE 2029-12-17, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Harrow Eye |
| FDA Application & Pathway | N022048 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2029-12-17 |
| Last Listed Patent or Exclusivity Date | 2029-12-17 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 527.6% 2-yr change) |